The project is focused on the clinical development of RNA AntiSense Oligonucleotides (ASO) targeting noncoding-RNAs, mainly applied to solid cancers. Specifically, our activity will develop and optimize RNA therapeutics, e.g., MALAT1 gapmers or miRNA mimic synthetic products or ASO-anti-miRNAs for the miR200 family. The experimental design includes a combination of ASO approach plus selective small […]
Read More